| Summary: | Introduction: diabetes is considered an epidemic in the world. Diabetic foot is a serious health problem in Cuba. Heberprot-p is a novel drug that can solve a medical need not covered worldwide. Objective: to determine the complication that occurred during therapy with heberprot-p. Method: a descriptive longitudinal study was performed in 108 patients treated with heberprot-p in “Manuel Piti Fajardo” Policlinic in Santo Domingo between January 2012 and December 2015, the sample consisted of 14 patients who had a non-satisfactory evolution. The information was obtained by the survey method and through the review of medical records and treatment registration cards. Results: 87% of the patients who received heberprot-p treatment had a satisfactory outcome; of patients with unsatisfactory outcome the main complication was local infection (100%); 64,3% were males and 78,6% were older than 60 years, 64,3% had more than 10 years of diabetes and the most prevalent risk factors were hyperglycemia, overweight and obesity (or both), followed by dyslipidemia and depression, respectively. Conclusions: it was determined that local infection was the most frequent complication and hyperglycemia was the main risk factor.
|
|---|